Multicenter Retrospective Study of Vascular Infections and Endocarditis Caused by Campylobacter spp., France

Emerg Infect Dis. 2023 Mar;29(3):484-492. doi: 10.3201/eid2903.221417.

Abstract

The incidence of campylobacteriosis has substantially increased over the past decade, notably in France. Secondary localizations complicating invasive infections are poorly described. We aimed to describe vascular infection or endocarditis caused by Campylobacter spp. We included 57 patients from a nationwide 5-year retrospective study on Campylobacter spp. bacteremia conducted in France; 44 patients had vascular infections, 12 had endocarditis, and 1 had both conditions. Campylobacter fetus was the most frequently involved species (83%). Antibiotic treatment involved a β-lactam monotherapy (54%) or was combined with a fluoroquinolone or an aminoglycoside (44%). The mortality rate was 25%. Relapse occurred in 8% of cases and was associated with delayed initiation of an efficient antimicrobial therapy after the first symptoms, diabetes, and coexistence of an osteoarticular location. Cardiovascular Campylobacter spp. infections are associated with a high mortality rate. Systematically searching for those localizations in cases of C. fetus bacteremia may be warranted.

Keywords: Campylobacter spp.; France; bacteria; bacterial infections; graft infections; infectious aortitis; non-HACEK endocarditis; thrombophlebitis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia* / diagnosis
  • Campylobacter Infections* / drug therapy
  • Campylobacter fetus
  • Campylobacter*
  • Endocarditis* / drug therapy
  • France
  • Humans
  • Multicenter Studies as Topic
  • Retrospective Studies

Substances

  • Anti-Bacterial Agents